Antibody therapy to protect muscles in Duchenne and related diseases

Who could benefit from this research

What this research studies

This NIH grant funds the preclinical development of monoclonal antibodies that block LTBP4 to reduce harmful TGF-β signaling in neuromuscular diseases. The work aims to translate lab findings into a therapy that could slow muscle damage and fibrosis in Duchenne and related muscular dystrophies. The project includes antibody design, binding studies, and bioassays to show that the antibodies correctly target the intended protein and modulate disease-related pathways. If the preclinical data look promising, the next steps would move toward early human testing to assess safety and potential benefits for patients. The grant is led by IKAIKA Therapeutics and focuses on translating a genetic modifier insight into a tangible treatment option.

Why it matters

Where this research is happening

• Ikaika Therapeutics INC
  Oak Park, United States Active

Researchers

• Principal investigator: Georganopoulou, Dimitra — Ikaika Therapeutics INC
• Study coordinator: Georganopoulou, Dimitra

Related research

Other NIH-funded projects on the same topics.

• Scalable non-viral gene delivery for a common muscular dystrophy

  A patient-focused project tests a non-viral therapy to reduce harmful DMPK RNA in muscle because this could lessen symptoms of myotonic dystrophy type 1.

  NIH research Kinea Bio, INC. · Mukilteo, UNITED STATES · NIH-11525063

• Human iPSC NMJ models to study neuromuscular diseases

  Scientists are building patient-friendly lab models using stem cells from humans to study how neuromuscular diseases like ALS affect the connection between nerves and muscles.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11394226

• Human nerve–muscle junctions grown from patient stem cells to model ALS and related neuromuscular diseases

  They are growing human nerve-to-muscle connections from patient stem cells to help develop better treatments for people with ALS and similar neuromuscular conditions.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11082176

• Creating a treatment for neuromuscular diseases using anti-LTBP4.

  This study is looking at a new treatment that targets a protein called LTBP4 to help improve muscle function and slow down Duchenne Muscular Dystrophy (DMD), so that patients can feel better and do more in their daily lives.

  NIH research Northwestern University at Chicago · Chicago, United States · NIH-11064924

• Using human stem cells to study communication between nerves and muscles in neuromuscular diseases.

  This study is exploring how special stem cells can help us create models of the connections between nerves and muscles, which are important for movement, to better understand diseases like ALS and find new ways to treat them.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-10727888

• Wearable monitoring of walking and arm movement in adults with neuromuscular or metabolic movement disorders

  This project uses a wrist/ankle wearable to continuously monitor walking and upper-limb movement in ambulant adults with neuromuscular diseases or obesity to see if digital measures like stride speed track real-life motor function.

  Recruiting Centre Hospitalier Universitaire de Liege · Liège · NCT07136844

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.